These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

463 related items for PubMed ID: 29733441

  • 21. Evaluation of Pharmacokinetic Interactions Between Lesinurad, a New Selective Urate Reabsorption Inhibitor, and Commonly Used Drugs for Gout Treatment.
    Shen Z, Tieu K, Wilson D, Bucci G, Gillen M, Lee C, Kerr B.
    Clin Pharmacol Drug Dev; 2017 Jul; 6(4):377-387. PubMed ID: 28074640
    [Abstract] [Full Text] [Related]

  • 22. Cardiovascular Disease in Gout and the Protective Effect of Treatments Including Urate-Lowering Therapy.
    Gupta MK, Singh JA.
    Drugs; 2019 Apr; 79(5):531-541. PubMed ID: 30868398
    [Abstract] [Full Text] [Related]

  • 23. Guideline development for the management of gout: role of combination therapy with a focus on lesinurad.
    Jones G, Panova E, Day R.
    Drug Des Devel Ther; 2017 Apr; 11():3077-3081. PubMed ID: 29123379
    [Abstract] [Full Text] [Related]

  • 24. Verinurad combined with febuxostat in Japanese adults with gout or asymptomatic hyperuricaemia: a phase 2a, open-label study.
    Shiramoto M, Liu S, Shen Z, Yan X, Yamamoto A, Gillen M, Ito Y, Hall J.
    Rheumatology (Oxford); 2018 Sep 01; 57(9):1602-1610. PubMed ID: 29868853
    [Abstract] [Full Text] [Related]

  • 25. Impact of non-adherence on the safety and efficacy of uric acid-lowering therapies in the treatment of gout.
    Hill-McManus D, Soto E, Marshall S, Lane S, Hughes D.
    Br J Clin Pharmacol; 2018 Jan 01; 84(1):142-152. PubMed ID: 28888218
    [Abstract] [Full Text] [Related]

  • 26. Lesinurad: A Novel Agent for Management of Chronic Gout.
    Haber SL, Fente G, Fenton SN, Walker EP, Weaver BM, Cano AJ, Vu K.
    Ann Pharmacother; 2018 Jul 01; 52(7):690-696. PubMed ID: 29482353
    [Abstract] [Full Text] [Related]

  • 27. Individualized treatment strategies for hyperuricemia informed by a semi-mechanistic exposure-response model of uric acid dynamics.
    Aksenov S, Peck CC, Eriksson UG, Stanski DR.
    Physiol Rep; 2018 Mar 01; 6(5):. PubMed ID: 29488355
    [Abstract] [Full Text] [Related]

  • 28. Comparison of topiroxostat and allopurinol in Japanese hyperuricemic patients with or without gout: a phase 3, multicentre, randomized, double-blind, double-dummy, active-controlled, parallel-group study.
    Hosoya T, Ogawa Y, Hashimoto H, Ohashi T, Sakamoto R.
    J Clin Pharm Ther; 2016 Jun 01; 41(3):290-7. PubMed ID: 27109450
    [Abstract] [Full Text] [Related]

  • 29. Efficacy and safety during extended treatment of lesinurad in combination with febuxostat in patients with tophaceous gout: CRYSTAL extension study.
    Dalbeth N, Jones G, Terkeltaub R, Khanna D, Fung M, Baumgartner S, Perez-Ruiz F.
    Arthritis Res Ther; 2019 Jan 07; 21(1):8. PubMed ID: 30616614
    [Abstract] [Full Text] [Related]

  • 30. Pharmacokinetics, Pharmacodynamics, and Tolerability of Concomitant Multiple Dose Administration of Verinurad (RDEA3170) and Allopurinol in Adult Male Subjects With Gout.
    Kankam M, Hall J, Gillen M, Yang X, Shen Z, Lee C, Liu S, Miner JN, Walker S, Clauson V, Wilson D, Nguyen M.
    J Clin Pharmacol; 2018 Sep 07; 58(9):1214-1222. PubMed ID: 29733447
    [Abstract] [Full Text] [Related]

  • 31. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial.
    Schumacher HR, Becker MA, Wortmann RL, Macdonald PA, Hunt B, Streit J, Lademacher C, Joseph-Ridge N.
    Arthritis Rheum; 2008 Nov 15; 59(11):1540-8. PubMed ID: 18975369
    [Abstract] [Full Text] [Related]

  • 32. Lesinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibition of urate transporters in the kidney.
    Miner JN, Tan PK, Hyndman D, Liu S, Iverson C, Nanavati P, Hagerty DT, Manhard K, Shen Z, Girardet JL, Yeh LT, Terkeltaub R, Quart B.
    Arthritis Res Ther; 2016 Oct 03; 18(1):214. PubMed ID: 27716403
    [Abstract] [Full Text] [Related]

  • 33. Potency on lowering serum uric acid in gout patients: a pooled analysis of registrative studies comparing febuxostat vs. allopurinol.
    Cutolo M, Cimmino MA, Perez-Ruiz F.
    Eur Rev Med Pharmacol Sci; 2017 Sep 03; 21(18):4186-4195. PubMed ID: 29028079
    [Abstract] [Full Text] [Related]

  • 34. Budget impact of adding lesinurad for second-line treatment of gout: a US health plan perspective.
    Klein RW, Kabadi S, Cinfio FN, Bly CA, Taylor DC, Szymanski KA.
    J Comp Eff Res; 2018 Aug 03; 7(8):807-816. PubMed ID: 29792516
    [Abstract] [Full Text] [Related]

  • 35. Integrated safety studies of the urate reabsorption inhibitor lesinurad in treatment of gout.
    Terkeltaub R, Saag KG, Goldfarb DS, Baumgartner S, Schechter BM, Valiyil R, Jalal D, Pillinger M, White WB.
    Rheumatology (Oxford); 2019 Jan 01; 58(1):61-69. PubMed ID: 30124941
    [Abstract] [Full Text] [Related]

  • 36. An allopurinol-controlled, multicenter, randomized, open-label, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: phase 2 exploratory clinical study.
    Kamatani N, Fujimori S, Hada T, Hosoya T, Kohri K, Nakamura T, Ueda T, Yamamoto T, Yamanaka H, Matsuzawa Y.
    J Clin Rheumatol; 2011 Jun 01; 17(4 Suppl 2):S44-9. PubMed ID: 21654269
    [Abstract] [Full Text] [Related]

  • 37. An allopurinol-controlled, randomized, double-dummy, double-blind, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: phase 3 clinical study.
    Kamatani N, Fujimori S, Hada T, Hosoya T, Kohri K, Nakamura T, Ueda T, Yamamoto T, Yamanaka H, Matsuzawa Y.
    J Clin Rheumatol; 2011 Jun 01; 17(4 Suppl 2):S13-8. PubMed ID: 21654265
    [Abstract] [Full Text] [Related]

  • 38. Efficacy and safety of lesinurad for the treatment of hyperuricemia in gout.
    Pérez-Ruiz F, Jansen T, Tausche AK, Juárez-Campo M, Gurunath RK, Richette P.
    Drugs Context; 2019 Jun 01; 8():212581. PubMed ID: 31191704
    [Abstract] [Full Text] [Related]

  • 39. Comparative efficacy and safety of lesinurad 200 mg and 400 mg combined with a xanthine oxidase inhibitor in hyperuricemic patients with gout: A Bayesian network meta-analysis of randomized controlled trials
.
    Song GG, Lee YH.
    Int J Clin Pharmacol Ther; 2019 Jul 01; 57(7):345-352. PubMed ID: 30990408
    [Abstract] [Full Text] [Related]

  • 40. Lesinurad: First Global Approval.
    Hoy SM.
    Drugs; 2016 Mar 01; 76(4):509-16. PubMed ID: 26861027
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 24.